Publications by authors named "Marc S Raab"

75Publications

B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives.

Int J Cancer 2020 Oct 30;147(8):2029-2041. Epub 2020 Apr 30.

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.33002DOI Listing
October 2020

FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas.

Acta Neuropathol 2020 01 31;139(1):175-192. Epub 2019 Aug 31.

Department of Human Genetics OE 6300, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00401-019-02067-zDOI Listing
January 2020

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

N Engl J Med 2019 08;381(8):727-738

From the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai (A.C., S.P., S.J.), and New York University Langone Medical Center (D.K.) - both in New York; the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (D.T.V.); the School of Medicine, National and Kapodistrian University of Athens, Athens (M.G., M. Dimopoulos); the Winship Cancer Institute, Emory University, Atlanta (A.K.N., S.L.); Massachusetts General Hospital Cancer Center (A.J.Y.), Tufts Medical Center (R.L.C.), and the Dana-Farber Cancer Institute (P.G.R.), Boston, and Karyopharm Therapeutics, Newton (M.G.K., S.S., L.L., S. Tang, C.P., J.-R.S.-M., M.C., H.C., Y.L., J.S.) - all in Massachusetts; Johns Hopkins University, Baltimore (C.A.H.); the University of Nantes, Nantes (P.M.), Hôpital Necker (L.F.), Hôpital Saint-Antoine (M.M.), and La Pitié-Salpêtrière Hospital (S.C.), Paris, University Hospital, Lille (T.F.), Centre Hospitalier Lyon Sud, Pierre-Benite (L.K.), and Centre Hospitalo-Universitaire Vandoeuvre-lès-Nancy, Nancy (A.P.) - all in France; the Mayo Clinic, Rochester, MN (D.D.); the University of Michigan, Ann Arbor (C.C.); the Mayo Clinic of Arizona, Phoenix (A.K.S.); Hackensack University Medical Center, Hackensack, NJ (J.R.); Washington University School of Medicine, St. Louis (R.V.); Lineberger Comprehensive Cancer Center at University of North Carolina-Chapel Hill, Chapel Hill (S. Tuchman); the University of Heidelberg, Heidelberg (M.S.R.), University Medical Center Hamburg-Eppendorf, Hamburg (K.C.W.), the University of Tübingen, Tübingen (K.C.W.), University Hospital Würzburg, Würzburg (M.S.), the University of Freiburg, Freiburg (M.E.), and Gemeinschaftspraxis Hämatologie-Onkologie, Dresden (T.I.) - all in Germany; the University of Leuven, Leuven (M. Delforge), Institut Jules Bordet, Université Libre de Bruxelles, Brussels (N.M.), University Hospital Ghent, Ghent (P.V.), and Centre Hospitalier Universitaire Université Catholique de Louvain Namur, Yvoir (C.D.) - all in Belgium; Vanderbilt University Medical Center, Nashville (R.F.C.); Sylvester Cancer Center, University of Miami, Miami (J.E.H.); the University of Alabama at Birmingham, Birmingham (L.J.C.); Yale School of Medicine, New Haven, CT (T.L.P.); Baylor University Medical Center, Dallas (M.L.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (G.S.); and University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria (K.P.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1903455
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1903455DOI Listing
August 2019

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma.

Int J Mol Sci 2019 Mar 12;20(5). Epub 2019 Mar 12.

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
https://www.mdpi.com/1422-0067/20/5/1248
Publisher Site
http://dx.doi.org/10.3390/ijms20051248DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429294PMC
March 2019

Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016.

Br J Haematol 2019 06 22;185(5):981-984. Epub 2018 Nov 22.

Department of Haematology, University College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15680DOI Listing
June 2019

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

N Engl J Med 2018 11;379(19):1811-1822

From the National and Kapodistrian University of Athens, Athens (M.A.D.); Karol Marcinkowski University of Medical Sciences, Poznań (D.D.), and Silesian Medical University, Katowice (S.G.) - both in Poland; University Hospital, Nantes (P.M.), and Centre Hospitalier Universitaire de Poitiers-La Milétrie, Poitiers (X.L.) - both in France; National Hospital Organization Disaster Medical Center (N.T.) and the Japanese Red Cross Medical Center (K.S.), Tokyo, and Ibaraki Prefectural Central Hospital, Kasama (M.H.) - all in Japan; Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal (R.L.); Heidelberg University Hospital, Heidelberg, Germany (M.S.R.); Dana-Farber Cancer Institute, Boston (P.G.R.); Bristol-Myers Squibb, Princeton, NJ (M.P.M., Y.-M.J., S.G.S., M.R., B.R.); and Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain (J.S.-M.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805762
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805762DOI Listing
November 2018

Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance.

Leukemia 2018 12 6;32(12):2717-2719. Epub 2018 Jul 6.

Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0202-1DOI Listing
December 2018

Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders.

Leuk Lymphoma 2018 11 4;59(11):2660-2669. Epub 2018 Apr 4.

a Department of Internal Medicine V , University Hospital Heidelberg , Heidelberg , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1443450DOI Listing
November 2018

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.

Ann Hematol 2018 May 23;97(5):839-849. Epub 2018 Jan 23.

Max-Eder-Group 'Experimental Therapies for Hematologic Malignancies', Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3237-5DOI Listing
May 2018

Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.

Hematol Oncol 2018 Feb 25;36(1):258-261. Epub 2017 Aug 25.

Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2473
Publisher Site
http://dx.doi.org/10.1002/hon.2473DOI Listing
February 2018

Asymmetric Centriole Numbers at Spindle Poles Cause Chromosome Missegregation in Cancer.

Cell Rep 2017 Aug;20(8):1906-1920

Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, 69120 Heidelberg, Germany; Department of Internal Medicine V, University of Heidelberg, 69120 Heidelberg, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2017.08.005DOI Listing
August 2017

Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.

Hematol Oncol 2018 Feb 7;36(1):210-216. Epub 2017 Jul 7.

Department of Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2462DOI Listing
February 2018

Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.

J Cancer Res Clin Oncol 2017 Dec 26;143(12):2521-2526. Epub 2017 Jun 26.

Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-017-2463-xDOI Listing
December 2017

Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability.

Eur J Med Chem 2017 Apr 22;130:240-247. Epub 2017 Feb 22.

Center for Nanomedicine and Theranostics & Department of Chemistry, Technical University of Denmark, Kemitorvet 207, DK-2800 Kgs, Lyngby, Denmark. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S02235234173012
Publisher Site
http://dx.doi.org/10.1016/j.ejmech.2017.02.055DOI Listing
April 2017

Oxygen bubbles to predict sensitivity to IMiDs.

Authors:
Marc S Raab

Blood 2017 02;129(8):923-925

HEIDELBERG UNIVERSITY HOSPITAL; GERMAN CANCER RESEARCH CENTER.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-01-760512DOI Listing
February 2017

Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.

Am J Hematol 2016 Nov 3;91(11):E473-E477. Epub 2016 Sep 3.

Medizinische Klinik V, University Hospital Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24533DOI Listing
November 2016

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.

Blood 2016 09 25;128(9):1226-33. Epub 2016 Jul 25.

Max-Eder Group "Experimental Therapies for Hematologic Malignancies," Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany; Department of Internal Medicine V, and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-02-698092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524534PMC
September 2016

Multiple myeloma: patient outcomes in real-world practice.

Br J Haematol 2016 Oct 13;175(2):252-264. Epub 2016 Jul 13.

'Seràgnoli' Institute of Hematology and Medical Oncology, Bologna University School of Medicine, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096152PMC
October 2016

Multiple myeloma: practice patterns across Europe.

Br J Haematol 2016 10 13;175(1):66-76. Epub 2016 Jun 13.

Department of Haematology, University College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14193DOI Listing
October 2016

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition.

Blood 2016 04 16;127(17):2155-7. Epub 2016 Feb 16.

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-12-686782DOI Listing
April 2016

Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.

Hematol Oncol 2016 Dec 18;34(4):200-207. Epub 2015 Mar 18.

Max-Eder-Group 'Experimental Therapies for Hematologic Malignancies', Department of Medicine V, Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2199DOI Listing
December 2016

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.

Oncotarget 2014 Nov;5(21):10237-50

Max-Eder Group Experimental Therapies for Hematologic Malignancies, German Cancer Research Center (DKFZ) and Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279369PMC
http://dx.doi.org/10.18632/oncotarget.2529DOI Listing
November 2014

T cell-based targeted immunotherapies for patients with multiple myeloma.

Int J Cancer 2015 Apr 19;136(8):1751-68. Epub 2014 Sep 19.

Department of Internal Medicine V, University Clinic Heidelberg, University of Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.29190DOI Listing
April 2015

Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.

J Clin Oncol 2013 Dec 21;31(34):4325-32. Epub 2013 Oct 21.

Kai Neben, Anna Jauch, Jens Hillengass, Nicola Lehners, Martin Granzow, Marc S. Raab, and Anthony D. Ho, University of Heidelberg; Thomas Hielscher, German Cancer Research Center; and Anja Seckinger, Hartmut Goldschmidt, and Dirk Hose,University of Heidelberg and National Center for Tumor Diseases, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.48.4923DOI Listing
December 2013

Targeting the BRAF V600E mutation in multiple myeloma.

Cancer Discov 2013 Aug 23;3(8):862-9. Epub 2013 Apr 23.

Department of General Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0014DOI Listing
August 2013

STIL is required for centriole duplication in human cells.

J Cell Sci 2012 Mar 20;125(Pt 5):1353-62. Epub 2012 Feb 20.

Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Dept. of Internal Medicine V, University of Heidelberg, 69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1242/jcs.104109DOI Listing
March 2012

Disparate SAR data of griseofulvin analogues for the dermatophytes Trichophyton mentagrophytes, T. rubrum, and MDA-MB-231 cancer cells.

J Med Chem 2012 Jan 17;55(2):652-60. Epub 2012 Jan 17.

Center for Nanomedicine and Theranostics & Department of Chemistry, Technical University of Denmark, Kemitorvet, Building 201, DK-2800 Kgs. Lyngby, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm200835cDOI Listing
January 2012

[Immunostimulating drugs and cytokines].

Ther Umsch 2011 Nov;68(11):655-8

Abteilung Innere Medizin V, Hämatologie, Onkologie, Rheumatologie, Universitätsklinikum Heidelberg.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1024/0040-5930/a000226DOI Listing
November 2011

Multiple myeloma.

Lancet 2009 Jul 21;374(9686):324-39. Epub 2009 Jun 21.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(09)60221-XDOI Listing
July 2009

Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.

Blood 2009 Feb 18;113(7):1513-21. Epub 2008 Nov 18.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2008-05-157040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2644079PMC
February 2009

The therapeutic role of targeting protein kinase C in solid and hematologic malignancies.

Expert Opin Investig Drugs 2007 Oct;16(10):1693-707

Dana-Farber Cancer Institute, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/13543784.16.10.1
Publisher Site
http://dx.doi.org/10.1517/13543784.16.10.1693DOI Listing
October 2007

Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.

Br J Haematol 2007 Oct;139(1):55-63

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1365-2141.2007.06747.x
Publisher Site
http://dx.doi.org/10.1111/j.1365-2141.2007.06747.xDOI Listing
October 2007